IP Library Patent Application 11898911
Patent Application
App. No. 11/898,911

Compositions comprising avermectin/azelaic acid compounds useful for treating, e.g., rosacea

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/898,911
Abstract

Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor.

Claims (16)

1 . A pharmaceutical/dermatological composition useful for the prevention/treatment of disorders of the skin in the absence of irritation and intolerance, comprising thus effective amounts of at least one avermectin compound and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor.

2 . The pharmaceutical/dermatological composition as defined by claim 1 , said at least one avermectin compound being selected from the group consisting of ivermectin, ivermectin, avermectin, abamectin, doramectin, eprinomectin and selamectin.

3 . The pharmaceutical/dermatological composition as defined by claim 2 , said at least one avermectin compound comprising ivermectin.

4 . The pharmaceutical/dermatological composition as defined by claim 1 , said at least one azelaic acid compound or salt or derivative thereof comprising free azelaic acid.

5 . The pharmaceutical/dermatological composition as defined by claim 1 , said at least one azelaic acid compound or salt or derivative thereof comprising a salt of azelaic acid.

6 . The pharmaceutical/dermatological composition as defined by claim 1 , said at least one avermectin compound comprising from 0.001% to 10% by weight thereof.

7 . The pharmaceutical/dermatological composition as defined by claim 6 , said at least one azelaic acid compound or salt or derivative thereof comprising from 0.01% to 40% by weight thereof.

8 . The pharmaceutical/dermatological composition as defined by claim 1 , formulated for topical application.

9 . The pharmaceutical/dermatological composition as defined by claim 1 , formulated as a gel.

10 . The pharmaceutical/dermatological composition as defined by claim 1 , formulated as an emulsion.

11 . The pharmaceutical/dermatological composition as defined by claim 1 , formulated as an aqueous or aqueous-alcoholic solution, a lotion, a serum, a cream, an ointment, a milk, a suspension, a dispersion, microcapsules or microparticles.

12 . The pharmaceutical/dermatological composition as defined by claim 1 , further comprising at least one active agent selected from the group consisting of antibiotics, anti-bacterial agents, anti-viral agents, anti-parasitic agents, anti-fungal agents, anaesthetics, analgesics, anti-allergic agents, retinoids, free-radical scavengers, anti-pruritic agents, keratolytic agents, anti-seborrhoeic agents, anti-histamines, sulfides, and immunosuppressant or anti-proliferative products.

13 . The pharmaceutical/dermatological composition as defined by claim 1 , further comprising at least one additive selected from the group consisting of chelating agents, antioxidants, sunscreens, preservatives, fillers, electrolytes, humectants, dyes, mineral or organic acids or bases, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, calmatives, skin-protecting agents, pro-penetrating agents, gelling agents, and mixtures thereof.

14 . A regime or regimen for the prevention/treatment of rosacea, common acne and/or seborrhoeic dermatitis, comprising administering to an individual in need of such treatment, a thus effective amount of at least one avermectin compound and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor.

15 . The regime or regimen as defined by claim 14 , comprising the prevention/treatment of rosacea.

16 . The pharmaceutical/dermatological composition as defined by claim 1 , said at least one avermectin compound comprising from 0.01% to 5% by weight thereof and said at least one azelaic acid compound or salt or derivative thereof comprising from 1% to 20% by weight thereof.

Assignments (3)
ASSET TRANSFER AGREEMENT Recorded Oct 3, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 057698/0295 →
CHANGE OF NAME Recorded Oct 3, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057698/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2008
From: KAOUKHOV, ALEXANDRE; PERNIN, COLETTE
To: GALDERMA S.A.
Reel/Frame 020531/0561 →